"Drug Approval" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Process that is gone through in order for a drug to receive approval by a government regulatory agency. This includes any required pre-clinical or clinical testing, review, submission, and evaluation of the applications and test results, and post-marketing surveillance of the drug.
| Descriptor ID |
D017277
|
| MeSH Number(s) |
E05.337.300 I01.880.604.605.250.250
|
| Concept/Terms |
Drug Approval- Drug Approval
- Approval, Drug
- Approvals, Drug
- Drug Approvals
- Food and Drug Administration Drug Approval
Drug Approval Process- Drug Approval Process
- Approval Process, Drug
- Approval Processes, Drug
- Drug Approval Processes
- Process, Drug Approval
- Processes, Drug Approval
New Drug Approval- New Drug Approval
- Approval, New Drug
- Approvals, New Drug
- Drug Approval, New
- Drug Approvals, New
- New Drug Approvals
|
Below are MeSH descriptors whose meaning is more general than "Drug Approval".
Below are MeSH descriptors whose meaning is more specific than "Drug Approval".
This graph shows the total number of publications written about "Drug Approval" by people in this website by year, and whether "Drug Approval" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 2 | 0 | 2 |
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2005 | 2 | 1 | 3 |
| 2006 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2008 | 1 | 0 | 1 |
| 2010 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
| 2012 | 1 | 0 | 1 |
| 2013 | 0 | 2 | 2 |
| 2014 | 1 | 0 | 1 |
| 2015 | 0 | 2 | 2 |
| 2017 | 0 | 2 | 2 |
| 2018 | 0 | 3 | 3 |
| 2019 | 1 | 3 | 4 |
| 2020 | 1 | 3 | 4 |
| 2021 | 3 | 0 | 3 |
| 2023 | 1 | 0 | 1 |
| 2024 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Drug Approval" by people in Profiles.
-
Ten years of experience with ruxolitinib since approval for polycythemia vera: A review of clinical efficacy and safety. Cancer. 2025 Jan 01; 131(1):e35661.
-
Syfovre Approval for Geographic Atrophy. JAMA Ophthalmol. 2024 Jul 01; 142(7):685-686.
-
The approval of lisocabtagene maraleucel in chronic lymphocytic leukemia. Clin Adv Hematol Oncol. 2024 Jul-Aug; 22(6):291-293.
-
Immunotherapy in locally advanced cervix cancer: A critical appraisal of the FDA indication based on ENGOT-CX11/GOG-3047/KEYNOTE-A18. Gynecol Oncol. 2024 Sep; 188:81-82.
-
Patterns of immunotherapy utilization for non-small cell lung cancer in Texas pre- and post-regulatory approval. Clin Transl Oncol. 2024 Aug; 26(8):1908-1920.
-
Project Confirm: Accelerated Drug Approvals for CML-Response. Clin Cancer Res. 2024 01 05; 30(1):237-238.
-
Project Confirm: Accelerated Drug Approvals for Chronic Myeloid Leukemia. Clin Cancer Res. 2023 06 13; 29(12):2179-2183.
-
Off-label is not always off-evidence: authorising paediatric indications for old medicines. Lancet Child Adolesc Health. 2023 06; 7(6):371-372.
-
Viewpoint: What Is Reasonable and Necessary for People Living with AD after the FDA Approves a Treatment? J Prev Alzheimers Dis. 2023; 10(3):344-345.
-
Impact of tissue-agnostic approvals for patients with gastrointestinal malignancies. Trends Cancer. 2023 03; 9(3):237-249.